Filing Flows › Aurinia Pharmaceuticals (AUPH) › License, collaboration and royalty revenue revenue
Aurinia Pharmaceuticals (AUPH) License, collaboration and royalty revenue revenue by quarter
Aurinia Pharmaceuticals' License, collaboration and royalty revenue revenue was $4.3M in Q3 2026 (third quarter 2026), +12% from Q2 2026. Over the last 7 quarters it ranged from $2.5M (Q1 2025) to $4.3M (Q3 2026).
| Quarter | License, collaboration and royalty revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.3M | +12% | +51% |
| Q2 2026 | $3.8M | -8% | +11% |
| Q1 2026 | $4.1M | +41% | +66% |
| Q4 2025 | $2.9M | +4% | — |
| Q3 2025 | $2.8M | -17% | — |
| Q2 2025 | $3.4M | +38% | — |
| Q1 2025 | $2.5M | — | — |
Q3 2026 at a glance
Aurinia Pharmaceuticals, Q3 2026: revenue $83.7M (+14% year over year), operating margin 42.3%, net earnings $31.7M, operating cash flow $46.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Aurinia Pharmaceuticals' License, collaboration and royalty revenue revenue?
Aurinia Pharmaceuticals' License, collaboration and royalty revenue revenue was $4.3M in Q3 2026 (third quarter 2026), +12% from Q2 2026.
How has Aurinia Pharmaceuticals' License, collaboration and royalty revenue revenue changed?
Over the last 7 quarters it ranged from $2.5M (Q1 2025) to $4.3M (Q3 2026).
Q3 2026 results → · How Aurinia Pharmaceuticals makes money →